Paper Details

  1. Home
  2. Paper Details

Sporadic visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).

Author: , HuangJiayan, KimBenjamin J, LevyNicole E, MaguireMaureen G, YingGui-Shuang

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Overview

A cohort within a randomized clinical trial of 1185 patients with neovascular age-related macular degeneration (AMD) found that approximately 10% of patients experienced sporadic vision loss during anti-vascular endothelial growth factor treatment. This was defined as a decline of ≥15 letters from the previous visit, followed by a return at the next visit to no more than 5 letters worse than the visit before the VA loss. Baseline predictors for sporadic vision loss included worse baseline VA, scar, intraretinal foveal fluid on OCT, and medical history of anxiety and syncope. Refraction decreased the likelihood of sporadic vision loss.
Paper Details　
Original Abstract of the Article :
PURPOSE: To evaluate transient, large visual acuity (VA) decreases, termed sporadic vision loss, during anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration (AMD). DESIGN: Cohort within a randomized clinical trial. METHODS: setting: Comparison of Age-R...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/24727261

データ提供：米国国立医学図書館（NLM）

Sporadic Vision Loss in AMD Treatment: Unveiling the Mysteries

Age-related macular degeneration (AMD) is a leading cause of vision loss. This study examines the phenomenon of sporadic vision loss, characterized by transient, large declines in visual acuity during anti-vascular endothelial growth factor (VEGF) treatment for neovascular AMD. The researchers analyzed data from the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) to identify risk factors associated with sporadic vision loss. Their findings reveal that several factors, including baseline visual acuity, scar presence, and intraretinal fluid, were associated with an increased risk of sporadic vision loss.

Sporadic Vision Loss: A Challenge in AMD Treatment

This study highlights the importance of understanding the underlying mechanisms of sporadic vision loss during AMD treatment. The identification of risk factors associated with this phenomenon provides valuable insights for clinicians managing AMD patients. These findings can help guide treatment decisions and enhance patient care, aiming to minimize the impact of sporadic vision loss on patients' visual function.

Navigating the Desert of Vision Loss: Understanding Sporadic Vision Loss in AMD

Imagine a camel traversing a desert landscape, its vision obscured by a sudden sandstorm. Sporadic vision loss in AMD patients can feel like a temporary but disorienting sandstorm, impacting their ability to navigate their surroundings. This study sheds light on the factors that can contribute to this phenomenon, providing valuable insights for clinicians and patients alike. By understanding these factors and implementing appropriate strategies, we can work to minimize the impact of sporadic vision loss and ensure the best possible visual outcomes for AMD patients.

Dr.Camel's Conclusion

This study is a testament to the continuous efforts to improve our understanding of AMD and its treatment. Sporadic vision loss, like a fleeting mirage in the desert, can be a perplexing and frustrating experience for patients. By identifying risk factors and implementing appropriate management strategies, we can work towards navigating the challenges of AMD treatment, aiming for clearer vision and a better quality of life for affected individuals.

Date :
  1. Date Completed 2014-08-22
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

24727261

DOI: Digital Object Identifier

NIHMS597209

Related Literature

Article Analysis
・Effective treatment of macular degeneration
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.